Identification and Functional Characterisation of Novel Glucokinase Mutations Causing Maturity-Onset Diabetes of the Young in Slovakia

Lucia Valentínová1,2, Nicola L. Beer2, Juraj Staník1,3, Nicholas D. Tribble2, Martijn van de Bunt2, Miroslava Hučková1,4, Amy Barrett2, Iwar Klimesˇ1,4, Daniela Gašperíková1,4, Anna L. Gloyn2,5*

1 Institute of Experimental Endocrinology, Slovak Academy of Science, Bratislava, Slovakia, 2 Oxford Centre for Diabetes Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom, 3 Children Diabetes Centre, First Department of Paediatrics, Comenius University, Bratislava, Slovakia, 4 Centre for Molecular Medicine, Slovak Academy of Sciences, Bratislava, Slovakia, 5 NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom

Abstract

Heterozygous glucokinase (GCK) mutations cause a subtype of maturity-onset diabetes of the young (GCK-MODY). Over 600 GCK mutations have been reported of which ~65% are missense. In many cases co-segregation has not been established and despite the importance of functional studies in ascribing pathogenicity for missense variants these have only been performed for <10% of mutations. The aim of this study was to determine the minimum prevalence of GCK-MODY amongst diabetic subjects in Slovakia by sequencing GCK in 100 Slovakian probands with a phenotype consistent with GCK-MODY and to explore the pathogenicity of identified variants through family and functional studies. Twenty-two mutations were identified in 36 families (17 missense) of which 7 (I110N, V200A, N204D, G223S, G258R, F419S, V244G, L315H, I436N) mutations were functionally evaluated. Basic kinetic analysis explained pathogenicity for 2 mutants which showed reduced glucokinase activity with relative activity indices (RAI) between 0.6 to <0.001 compared to wild-type GCK (1.0). For the remaining 2 mutants additional molecular mechanisms were investigated. Differences in glucokinase regulatory protein (GKRP) –mediated-inhibition of GCK were observed for both L315H & I436N when compared to wild type (IC50 14.6±0.1 mM & 20.3±1.6 mM vs.13.3±0.1 mM respectively [p<0.03]). Protein instability as assessed by thermal lability studies demonstrated that both L315H and I436N show marked thermal instability compared to wild-type GCK (RAI at 55°C 8.8±0.8% & 3.1±0.4% vs. 42.5±3.9% respectively [p<0.001]). The minimum prevalence of GCK-MODY amongst Slovakian patients with diabetes was 0.03%. In conclusion, we have identified 22 GCK mutations in 36 Slovakian probands and demonstrate that combining family, bioinformatic and functional studies can aid the interpretation of variants identified by molecular diagnostic screening.

Citation: Valentínová L, Beer NL, Staník J, Tribble ND, van de Bunt M, et al. (2012) Identification and Functional Characterisation of Novel Glucokinase Mutations Causing Maturity-Onset Diabetes of the Young in Slovakia. PLoS ONE 7(4): e34541. doi:10.1371/journal.pone.0034541

Editor: Farid F. Chehab, University of California San Francisco, United States of America

Received December 22, 2011; Accepted March 1, 2012; Published April 6, 2012

Copyright: © 2012 Valentínová et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded in Oxford by the Medical Research Council (81696), the European Foundation for the Study of Diabetes (Albert Renold Travel Fellowship awarded to LV), and the Wellcome Trust (095101/Z/10/Z). The research leading to these results has also received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement n°223211, CEED3. ALG is a Wellcome Trust Senior Fellow in Basic and Biomedical Science. This work was funded in Slovakia by the Slovak Diabetes Association and the Scientific Grant Agency of the Ministry of Education, Science, Research and Sports of the Slovak Republic, and the Slovak Academy of Sciences VEGA2/0151/11. This publication is also a result of the project implementation TRANSENDGEN/26240220051/supported by the Research & Development Operational Programme funded by the European Regional Development Fund ERDF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: anna.gloyn@drf.ox.ac.uk

Introduction

Heterozygous inactivating mutations in the glucokinase gene (GCK) are one cause of maturity-onset diabetes of the young (MODY) characterized by stable elevated fasting plasma glucose levels [1,2]. Micro and macrovascular complications are rare and patients can usually be treated by diet modification alone [3]. A molecular diagnosis is important because there are implications for treatment, prognosis and family members [3]. The prevalence of GCK-MODY is difficult to assess as the mild hyperglycaemia and absence of symptoms mean that many patients are not diagnosed. Large scale population based studies have not been performed but a number of studies have ascertained the prevalence of GCK-MODY in subjects with impaired glucose tolerance and diabetes [4,5,6,7,8,9,10,11]. There are differences in prevalence across these studies which likely reflect both the age of the population tested and the ascertainment criteria [12,13,14].

Glucokinase is a key enzyme in glycolysis which has been termed the pancreatic glucose sensor on account of its kinetic properties which result in the threshold for glucose stimulated insulin release (GSIR) being around 5 mmol/L [15]. Heterozygous inactivating GCK mutations shift the set point for GSIR, resulting in elevated fasting plasma glucose levels (typically between 5.5–8.0 mmol/L in individuals with GCK mutations [16,17]). The majority of individuals with GCK-MODY have a small (<3.5 mmol/L) 2 hour glucose increment following an oral

MODY in subjects with impaired glucose tolerance and diabetes [4,5,6,7,8,9,10,11]. There are differences in prevalence across these studies which likely reflect both the age of the population tested and the ascertainment criteria [12,13,14].

Glucokinase is a key enzyme in glycolysis which has been termed the pancreatic glucose sensor on account of its kinetic properties which result in the threshold for glucose stimulated insulin release (GSIR) being around 5 mmol/L [15]. Heterozygous inactivating GCK mutations shift the set point for GSIR, resulting in elevated fasting plasma glucose levels (typically between 5.5–8.0 mmol/L in individuals with GCK mutations [16,17]). The majority of individuals with GCK-MODY have a small (<3.5 mmol/L) 2 hour glucose increment following an oral
glucose tolerance test (OGTT) which can help distinguish them from patients with other forms of MODY [10].

Over 600 GCK mutations have been reported and in a recent review by Oshak and colleagues over 65% (402/620) are missense, with 56% only been reported in a single family [12]. There is increasing recognition of the difficulties in ascribing pathogenicity to missense variants uncovered through medical resequencing projects. Despite the importance of establishing co-segregation this is often over looked and functional studies have only been performed for a minority (<10%) of missense mutations [12]. A recent study has highlighted the importance of using a combination of approaches to correctly assign pathogenicity for GCK missense mutations [19]. In this study, we report an investigation of the minimum prevalence of GCK-MODY in Slovakia followed by an exploration of the pathogenicity of identified variants through family, bioinformatic and functional studies.

Materials and Methods

Subjects

One hundred probands collected between years 2005–2010 underwent diagnostic screening for GCK mutations following referral from their diabetologist. Selection criteria for testing were persistent and stable fasting hyperglycemia (5.5–10.0 mmol/L), HbA1c <8% [64 mmol/mol] (DCCT scale), age of diagnosis <35 years, and where on insulin treatment, the dose was <0.4 IU/Kg/day. Informed written consent was obtained from all subjects. For subjects under the age of 18 years written consent was obtained from either a parent or legal guardian.

Mutation Screening

Genomic DNA was extracted from peripheral blood using the Flexi Gene kit (Qiagen Ltd, Crawley, UK). The GCK neuroendocrine promoter, exons 1a and 2–10, and all intron-exon boundaries were amplified by PCR using previously published primers [20], and sequenced bi-directionally. Sequences were compared to the reference genomic GCK sequence (NM_000162.3) using SeqScape (version 2.1.1; Applied Biosystems). Partial or entire GCK deletions were excluded by multiplex ligation-dependent probe amplification (MLPA) using the P241-B MODY kit (MRG-Holland, Amsterdam, The Netherlands). Results were analyzed using GeneMarker version 1.95 (Soft Genetics, State College, PA, USA).

Phenotypic characterisation

Plasma glucose concentrations were measured via the glucose oxidase method (Hitachi 911, Hitachinaka, Japan), whilst cholesterol, HDL-cholesterol and triglyceride levels were measured using standard enzymatic protocols (DiaSys diagnostic systems, Holzheim, Germany; Randox Laboratories Ltd. Crumlin, UK).

In silico structural analysis

All missense mutations were analysed in silico using SIFT, PolyPhen, and Mutation Taster [http://sift.jcvi.org/, http://genetics.bwh.harvard.edu/pph/ and http://www.mutationtaster.org/ respectively]. Three-dimensional structural analysis was performed using PyMOL version 1.2 (DeLano Scientific, South San Francisco, CA, USA).

Preparation of recombinant proteins

Two preparations of human wild-type and each GCK mutant were generated as recombinant glutathionyl S-transferase-tagged fusion proteins using previously-described protocols [21,22,23]. Recombinant human wild-type glucokinase regulatory protein (GKRP) was also prepared as previously published [24,25].

Enzyme kinetics

The kinetic properties of each GCK enzyme were determined using glucose 6-phosphate dehydrogenase-coupled assays [21,22]. The relative activity index (RAI) for each enzyme and the predicted threshold for glucose stimulated insulin release (GSIR) were calculated as previously described [17]. Inhibition assays with human GKRP were performed in line with previous studies [24,25,26].

Thermolability Assays

Thermal instability assays were carried out using previously described protocols [22,27], but with the following modifications. Each GCK enzyme was incubated over a 40–63°C temperature range for 30 minutes. Immediately after incubation, enzymes were diluted in an assay containing 100 mmol/L HEPES, 6 mmol/L MgCl₂, 150 mmol/L KCl, 2 mmol/L DTT (prior to GCK activity measurement) [22,28,29].

GCK-MODY frequency data

The minimum prevalence of GCK-MODY in Slovakia was calculated based on available data for the total number of diabetic patients, and the total number of inhabitants in Slovakia based on the Slovak National Health Information Center (NCZI, www.nczisk.sk).

Statistical Analysis

Continuous variables are reported as mean plus or minus the standard error of the mean (SEM). Comparisons amongst variables were carried out using independent sample t-tests on SPSS software (version 17.0, IBM, Chicago, IL, USA). Inconvenient variables are reported as median with a given range.

Results

GCK mutational screening and clinical characterisation

Mutational screening identified 22 GCK mutations in 36 of the probands (Table 1); 17 missense, 1 frame-shift, 2 in frame deletions, 1 promoter and 1 splice-site. Seven of these mutations were novel (I110N, V200A, N204D, G258R, F419S, c.580-2A>G, c.1113-1114delIGG), they were also absent from 200 control chromosomes from normoglycaemic individuals. No variants were present in the October 2011 release of the 1000 Genomes project (http://www.1000genomes.org/). All novel mutations except G258R were identified in a single family, whilst G258R was identified in 2 unrelated families. Parental DNA was available for 22 probands (covering 14/22 mutations) and co-segregation was established in all cases (Figure S1). No partial or whole GCK deletions were identified. The clinical and biochemical characteristics of the GCK mutation carriers are presented in Table 2. The median proband age is consistent with other studies which have evaluated diabetes subtype [30].

In silico analysis of all missense mutations

In silico analysis of all missense mutations was performed using a suite of bioinformatic tools. Analysis in SIFT, PolyPhen and Mutation Taster revealed that for the majority of mutations there was consensus between the different bioinformatic tools but for 4 mutations (R43H, V200A, G223S, V244G) at least one program did not predict a clear impact on protein function (Table S1).
Along with the novel missense mutations these were selected for kinetic evaluation.

Kinetic Characterisation

The basic kinetic profiles of recombinant wild type and the mutant GCK proteins are given in Table 3. Seven of the nine mutant proteins (I110N, V200A, N204D, G223S, V244G, G258R, F419S) were shown to be kinetically inactivating, with a decreased rate of catalysis (Kcat) and/or a decreased affinity for glucose (increased $S_{0.5}$). Of note G258R-GCK and N204D-GKC had extremely low affinities for glucose, with $S_{0.5}$ values of $\geq 1000$ mmol/L. Interestingly, I110N had an increased affinity for ATP, but was still calculated as being kinetically inactivating as the mutant enzyme had a very low $K_{cat}$. Two mutant enzymes, L315H-GCK and I436N-GCK displayed near-normal kinetics, with similar glucose affinities, Hill number ($n_H$), $K_{cat}$, and only a marginally decreased affinity for ATP, compared with the wild-type enzyme.

To elucidate the molecular mechanism for these two mutants exhibiting near-normal kinetics (L315H and I436N), their interaction with the endogenous hepatic regulator GKRP and their effect on protein stability were explored. Both L315H-GCK and I436N-GCK displayed near-normal kinetics, with similar glucose affinities, Hill number ($n_H$), $K_{cat}$, and only a marginally decreased affinity for ATP, compared with the wild-type enzyme.

To elucidate the molecular mechanism for these two mutants exhibiting near-normal kinetics (L315H and I436N), their interaction with the endogenous hepatic regulator GKRP and their effect on protein stability were explored. Both L315H-GCK and I436N-GCK displayed near-normal kinetics, with similar glucose affinities, Hill number ($n_H$), $K_{cat}$, and only a marginally decreased affinity for ATP, compared with the wild-type enzyme.

Thermal instability assays

To explore whether protein instability could contribute to the mutational mechanism behind the I436N and L315H mutations, thermal-lability assays were performed over a 40–63°C temperature range for both mutant proteins and the known instability mutant E300K-GCK [31]. Analysis of these data showed that both L315H-GCK and I436N-GCK demonstrated marked thermal instability compared to wild-type GCK (Figure 2). The relative activity indices of both mutant enzymes was greatly reduced at 55°C, with values of 8.8±0.8% and 3.1±0.4% respectively compared to 42.5±3.9% for wild-type GCK ($p<0.001$).

Structural analysis

To understand the extremely low rate of catalysis for N204D-GCK and G258R-GCK we investigated the impact of these mutations on the structure of glucokinase. Modeling established that both residues G258 and N204 are located in close proximity to the glucose binding site (Figure S2). Structural analysis of the N204 residue revealed that mutation from asparagine to arginine cause a gain of one extra polar bond with residue N254 which is located in the neighboring beta sheet (Figure S2).

Minimum prevalence of GCK-MODY in Slovakia

GCK mutations were identified in 36 of the 100 probands screened and mutation testing in family members identified a
further 72 individuals with GCK mutations. With 337,187 patients with diabetes in Slovakia (Slovak National Health Information Center, 2010), and GCK-MODY confirmed in 108 individuals, this represents 0.03% of all diabetic patients. Recalculated to the number of inhabitants in Slovakia (5.4M, Slovak National Health Information Center, 2008), the minimum prevalence of the GCK-MODY is estimated to be 20.0 cases per million.

### Table 2. Clinical and biochemical parameters of Slovakian GCK mutation carriers.

|                                | Probands with GCK mutations | Family members with GCK mutations | Number data available on |
|--------------------------------|-----------------------------|----------------------------------|--------------------------|
|                                | n = 36                      | n = 72                           |                          |
| Age of diabetes diagnosis (yr) | 11.0 (4–45)                 | 26.5 (5–81)                      | 40¹                      |
| Age at investigation (yr)      | 16.5 (4–47)                 | 35.0 (1–86)                      | 72                       |
| BMI (kg/m²)                    | 19.6 (14.3–29.3)            | 23.4 (15.2–47.4)                | 44                       |
| HbA1c (%)                      | 6.4 (5.1–7.7) *             | 6.5 (5.0–9.7)                    | 16                       |
| Fasting plasma glucose (mmol/L)| 6.9 (5.5–9.8)               | 7.0 (5.2–11.8)                  | 65                       |
| Cholesterol (mmol/L)           | 4.1 (3.0–5.9)               | 4.5 (3.0–7.3)                   | 64                       |
| Triglycerides (mmol/L)         | 0.8 (0.3–2.4) *             | 0.9 (0.2–10.0)                  | 64                       |
| HDL-cholesterol (mmol/L)       | 1.2 (0.5–2.0)¹²            | 1.1 (0.6–2.1)                   | 64                       |

Data are presented as median values (range).
*Data only available for 35 probands.
¹Data only available for 33 probands.
²For the remaining 32 subjects, diabetes/impaired glucose tolerance was not detected prior to genetic testing.
BMI = body mass index, HbA1c = glycated hemoglobin A1c, HDL = High Density Lipoprotein, OHA = oral hypoglycaemic agents.

### Table 3. Kinetic characterisation of GCK-MODY mutations.

| GCK-GST | $S_{0.5}$ [mmol/L] | Hill number | $ATP_{Km}$ [mmol/L] | $K_{cat} S_{0.5}$ [s⁻¹] | Relative Activity Index (RAI) |
|---------|-------------------|-------------|---------------------|------------------------|-----------------------------|
| WT      | 7.69±0.10         | 1.67±0.01   | 0.44±0.01           | 65.78±0.84             | 1                           |
| I110N   | 14.87±0.25        | 1.37±0.03   | 0.03≤<0.01          | 3.07±0.04              | 0.02                        |
| V200A** | 78.3±0.97         | 1.28±0.01   | 0.69±0.07           | 56.85±0.81             | 0.01                        |
| N204D   | NO                | NO          | 5.42±0.10           | NO                     | NO                          |
| V244G*  | 12.77±0.33        | 1.52±0.02   | 0.4±0.01            | 75.71±1.36             | 0.43                        |
| G258R   | NO                | NO          | NO                  | NO                     | NO                          |
| G223S   | 16.5±0.16         | 1.46±0.02   | 0.47±0.01           | 74.45±1.63             | 0.25                        |
| L315H   | 8.09±0.06         | 1.67±0.01   | 0.50±0.01           | 69.21±0.63             | 0.89                        |
| F419S²  | 161.50±1.64       | 1.12±0.01   | 6.14±0.23           | 82.10±0.80             | <0.01                       |
| H436N   | 7.84±0.25         | 1.66±0.02   | 0.50±0.03           | 73.77±0.73             | 1.07                        |

Data are given as mean ± SEM measured in n=12 experiments. GCK-GST enzymes were prepared as 3 (WT)/2 (G258R)/1 (others) independent protein expressions. Glucose $S_{0.5}$ values were normally measured in the glucose range 0–100 mmol/L with 5 mmol/L ATP, however for some mutant enzymes the glucose range was increased to 0–300 mmol/L (*), 0–600 mmol/L (**), or 0–1000 mmol/L with 25 mmol/L ATP (²). NO = data not obtainable due to the severity of the kinetic inactivation which prevented the data from reaching a plateau even with a 10-fold increase in glucose concentration.

doi:10.1371/journal.pone.0034541.t003

doi:10.1371/journal.pone.0034541.t002
Discussion

It is important to identify patients with GCK-MODY as the diagnosis affects clinical management, prognosis and has implications for family members. We have screened 100 Slovakian probands with a phenotype consistent with GCK-MODY and identified variants in 36% (36/100) of cases. The majority (77%), of variants are missense and a recent study has highlighted the importance of using a combination of family, bioinformatic and functional studies to correctly assign pathogeneticy [19].

Parental DNA was available for 22 of the probands covering 14 of the 22 mutations and co-segregation was established in all cases. In two families there were individuals with diabetes who were not mutation carriers (Figure S1). Clinical data supports these individuals as having type 2 diabetes (phenocopies) rather than GCK-MODY (details given in Figure S1). A suite of bioinformatic tools (SIFT, PolyPhen, Mutation Taster) were used to assess the impact of all missense variants on protein function. These analyses included conservation of amino acid residues across species (SIFT, Mutation Taster), change in protein structure and function (PolyPhen, Mutation Taster) and effects on splicing or mRNA expression (Mutation Taster) [32,33,34]. SIFT and PolyPhen gave similar results predicting the vast majority of mutations to be damaging or possibly damaging (R43H, G223S) and predicting one mutation (V200A) to be tolerated. In contrast the newer program Mutation Taster predicted all mutations to be damaging.

Although bioinformatic prediction softwares are a useful tool the gold standard in assigning pathogenicity to mutations is to demonstrate genetic evidence (i.e. co-segregation in families) and an impact on protein function. Establishing co-segregation for late on-set disorders can be difficult due to problems in correctly assigning affection status and incomplete penetrance. However, with GCK-MODY the assignment of affection status is facilitated by a phenotype (raised fasting plasma glucose) which is easy to measure and presents from birth. Despite this it can still be difficult within a clinical setting to recruit family members for testing. We were able to test parental DNA for 22 of the 36 probands, which

![Figure 1. Inhibition of wild type, I436N and L315H glucokinase proteins by human GKRP. Data are shown as mean ± SEM, and were obtained from 4 independent measurements. Independent t-tests were used to ascertain differences between GKRP-mediated inhibition of both mutants versus that obtained with the wild-type GCK enzyme.](doi:10.1371/journal.pone.0034541.g001)

![Figure 2. Assessment of thermostability for GCK-GST mutant proteins. Proteins were incubated for 30 minutes over a range of temperatures (40–60 °C). Given data are means ± SEM, and were obtained from 6 independent measurements. The previously reported thermal instability mutant E300K [31](pink) was used as a positive control. The level of significance at each temperature point (mutants versus wild-type GCK activity) was calculated using an independent t-test.](doi:10.1371/journal.pone.0034541.g002)
covered 14 of the 22 mutations, and confirm co-segregation in all cases. Importantly this included all novel mutations and those with ambiguous in silico predictions. To complement our genetic and in silico studies we selected all novel missense mutations and those for which there was not a clear consensus on pathogenicity from bioinformatic analysis for further study. The previously reported R143H mutation was not included in our kinetic analysis as recent unpublished studies have shown this mutation to be kinetically inactivating (Nicola Beer, Anna Glyon unpublished observations) [35].

Basic kinetic characterisation of the mutant glucokinase proteins demonstrated that seven of the nine mutations studied were clearly kinetically inactivating due to either defects in activity or affinity for glucose. Previous studies have also identified GCK mutations causal for GCK-MODY which have near normal or paradoxical kinetics [17,28,29]. In some cases additional functional studies have demonstrated defects in post-translational regulation by GKRP and small molecular activators and/or protein and catalytic stability [28,29,31,36]. We therefore investigated the effect of the L315H and I436N mutations on the regulation of glucokinase by its regulatory protein GKRP. Our studies demonstrated differences in GKRP inhibition of GCK for both mutations. It has previously been suggested that defects in post-translational regulation of GCK by GKRP can lead to catalytic instability which could contribute to the molecular mechanism for these mutations [36].

Protein instability was assessed using previously validated thermolability assays and demonstrated that both L315H-GCK and I436N-GCK displayed marked thermo-instability which could account for their inactivating properties. Mathematical modeling incorporating this instability predicted that the threshold for GSIR would be ~7.0 mmol/L for both mutant proteins, which is in line with the clinical data. Further studies in a cellular model would be required to conclusively demonstrate that these mutations results in protein and/or catalytic instability, but our data, supported by previous studies, is highly suggestive of defects in catalytic and protein stability for these two mutants.

For the two proteins N204D-GCK & G258R-GCK for which kinetic parameters could not be fully determined structural modeling gave potential explanations for the extremely low catalytic activity of the two mutant proteins. The glucose binding site is located in the inter domain cleft of the enzyme and is composed of residues of the large domain (E256, E290), the small domain (T168, K165) and connecting region II (N204, D205) [37]. Connecting region II has been proposed to play an important role in the conformational changes required for GCK to move from its inactive to active form [37]. The critical role of residue N204 in the glucokinase molecule is further supported by our studies which show a severe impact of mutation at this residue on enzyme kinetics and additionally by the clinical phenotype of GCK-MODY observed in the patient with the N204D GCK mutation. Structural analysis of G258R-GCK, revealed that this mutation also lies in close proximity to the glucose binding site and that mutation from glycine to arginine results in occlusion of the glucose binding pocket and a subsequent spatial barrier for glucose binding.

The minimum prevalence of GCK mutation carriers was determined as 0.03% of all diabetic patients in Slovakia and is to date the first estimation of prevalence of GCK-MODY in a diabetic population. The prevalence of GCK mutation carriers calculated from an Austrian-German diabetes registry was 0.4% but this study only included patients under the age of 20 years [38]. We calculated the minimum prevalence of the GCK-MODY in Slovakia as 20.0 cases per million which is higher than in two recent studies from the UK [39,40]. This number is still very likely to be underestimated since a substantial proportion of cases will remain undiagnosed as GCK-MODY is largely an asymptomatic disorder. Shield and colleagues reported 6.4 cases per million with GCK-MODY [39]. The minimum prevalence of GCK-MODY determined in Slovakia (one GCK mutation carrier for every 53,763 inhabitants) is also higher than approximations from Kropff and colleagues who found among one mutation carrier per 118,927 inhabitants [40]. The median age of diabetes diagnosis in the current study was younger than that of the general diabetic population. Previous work has demonstrated a higher pick up rate for GCK-MODY in patients diagnosed at a younger age [13,14]. However, since GCK-MODY is often asymptomatic it is likely that we have still underestimated the prevalence of GCK-MODY as our study only includes individuals who have been referred by a Diabetologist for genetic screening. Population studies are required to accurately determine the prevalence of GCK mutations. Interestingly, two non-synonymous mutations, L315H and I436N, have previously been identified only in Czech families, and a recent study showed that L315H is one of the most prevalent GCK mutations in the Czech population [41]. This finding could suggest a potential existence of founder effect in Slovak and Czech families.

In conclusion, we provide the first evaluation of the prevalence of GCK-MODY in Slovakia and demonstrate that family, bioinformatic and functional studies can be used in combination to assign pathogenicity to missense GCK mutations.

Supporting Information

Figure S1 Pedigrees demonstrating co-segregation data for GCK mutations with elevated fasting glycaemia for 19/36 probands. Co-segregation data for 3 families with the −71G>C promoter mutation has previously been reported [42]. SQUARES represent males, circles females, shaded shapes represent individuals with fasting hyperglycaemia. Fasting plasma glucose levels (mmol/L) are given in blue underneath each individual. Symbols shaded ingrey –represent individuals with fasting hyperglycaemia but with no GCK mutation (phenocopies). Probands are indicated by an arrow and the letter P. IFG denotes individuals with impaired fasting glycaemia. NA= not available, NT = not tested, * = not monitored for IFG or DM. Additional clinical information on subjects with fasting hyperglycaemia but no GCK mutations: Family R92 II:3 - lipid profile: cholesterol 0.72 mmol/L (ref. <5.29), triglycerides 9.62 mmol/L (ref. <1.7), HDL-cholesterol 0.82 mmol/L (<1.0), BMI 29.4 kg/m²; Family R227 I:2 - BMI 32 kg/m², age of diagnosis 62 years, currently treated with metformin, also treated for hypertension and dyslipidemia (TIF)

Figure S2 Structural analysis of wild-type, G258R and N204D GCK mutants. A The closed (active) crystal structure of glucokinase (1v4s [37]) is shown in green, with bound-glucose represented by black spheres and GKA (yellow) bound in allosteric activator site. B Glucokinase structure zoomed to residue 258, where wild-type amino acid glycine and mutant arginine is represented by red and pink respectively. C glucokinase structure zoomed to residue 204, with represented side-chain of all amino acids in polar contact. Wild type amino acid N204 (red) showed polar bonds (yellow) to amino acids V207 (blue) and A208 (orange) and 4 solvent molecules (light blue spheres). Mutagenesis to D204 caused a loss of one of two polar bonds of the solvent molecule and a gain of polar bond (indicated by yellow arrow) with N254 (cyan) which is located in the neighboring beta sheet. (TIF)
Table S1  In silico analysis of all missense mutations found in Slovakian patients.

(DOC)

Acknowledgments

We acknowledge the following clinics for referring patients for genetic testing: L. Barak, V. Sandrikova, D. Reptisova, M. Mistrik, M. Smolcdasova, V. Vojtkova, E. Jancova, E. Mendelova, M. Hudakova. We also thank the technical assistance of Ivana Masinudova, Alice Mikutova, Boris Valentini and Martina Balogova for sample handling and DNA isolation.

References

1. Froogel P, Vailliaux M, Sun F, Velho G, Zouali H, et al. (1992) Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Hum Mol Genet 1: 1073–1076.
2. Ellard S, Bellanne-Chantelois C, Hattersley AT (2008) Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51: 546–553.
3. Murphy R, Butler K, Hattersley AT (2008) Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 4: 200–213.
4. Pruhova S, Ek J, Lebl J, Sumnik Z, Saudek F, et al. (2005) Genetic epidemiology of MODY in the Czech republic: new mutations in GCK gene of MODY genes HNF-4alpha, GCK and HNF-1alpha. Diabetologia 48: 291–295.
5. Sagen JV, Bjorkhaug L, Molnes J, Raeder H, Grevle L, et al. (2008) Diagnostic screening of G6PC2/GCK mutations in the Norwegian MODY Registry. PLoS ONE 3: e2449.
6. Johansen A, Ek J, Mortensen HR, Pedersen O, Hansen T (2005) Half of clinically defined maturity-onset diabetes of the young patients in Denmark do not have mutations in HNF4A, GCK, and TCF1. J Clin Endocrinol Metab 90: 4697–4614.
7. Costa A, Bescos M, Velho G, Chevre J, Vital J, et al. (2000) Genetic and clinical characterisation of maturity-onset diabetes of the young in Spanish families. Eur J Endocrinol 142: 380–386.
8. Massa O, Mecchi F, Cuesta-Munoz A, Caumo A, Ceretta F, et al. (2001) High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetes (SIEDP). Diabetologia 44: 890–905.
9. Mantovani V, Salardi S, Cerreta V, Bastia D, Cenci M, et al. (2003) Identification of eight novel glucokinase mutations in Italian children with maturity-onset diabetes of the young. Hum Mutat 22: 338.
10. Thomson KL, Glyn AL, Colclough K, Batten M, Allen LI, et al. (2003) Identification of 21 glucokinase (GCK) mutations in UK and European Caucasians with maturity-onset diabetes of the young (MODY). Hum Mutat 24: 417.
11. Froogel P, Zouali H, Vissutti N, Velho G, Vailliaux M, et al. (1993) Familial hyperglycaemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med 328: 697–702.
12. Osbik KK, Colclough K, Saint-Martin C, Beer NL, Bellanne-Chantelois C, et al. (2009) Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia hyperglycaemia. Hum Mutat 30: 1512–1526.
13. Glyn AL, van de Bunt M, Stratton IM, Lonie L, Tucker I, et al. (2009) Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia. Diabetologia 52: 177–174.
14. Feigllova E, Pruhova S, Ditertova L, Lebl J, Pinterova D, et al. (2006) Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur J Pediatr 165: 446–452.
15. Matschinsky FM (2002) Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 51 Suppl 3: S394–404.
16. Byrne MM, Sturis J, Clement K, Vissutti N, Pueyo ME, et al. (1994) Insulin secretory abnormalities in subjects with hyperglycaemia due to glucokinase mutations. Journal of Clinical Investigation 93: 1120–1130.
17. Glyn A, Odlid S, Buettger C, Njalstad PR, Shiota C, et al. (2004) Glucokinase and the regulation of blood sugar: A mathematical model predicts the threshold for glucose stimulated insulin release for GCK gene mutations that cause hyper- and hypoglycaemia. In: Magnuson M, Matschinsky F, eds. Glucokinase and glycemic Diseases: from the basics to novel therapeutics. Diabetes 55: 1713–1722.
18. Byrne MM, Sturis J, Clement K, Vissutti N, Pueyo ME, et al. (1994) Insulin secretory abnormalities in subjects with hyperglycaemia due to glucokinase mutations. Journal of Clinical Investigation 93: 1120–1130.
19. Glyn AL, Odlid S, Buettger C, Njalstad PR, Shiota C, et al. (2004) Glucokinase and the regulation of blood sugar: A mathematical model predicts the threshold for glucose stimulated insulin release for GCK gene mutations that cause hyper- and hypoglycaemia. In: Magnuson M, Matschinsky F, eds. Glucokinase and glycemic Diseases: from the basics to novel therapeutics. Karger. pp 92–109.
20. Liang Y, Kesavan P, Wang LQ, Niswender K, Tanizawa Y, et al. (1995) Variable effects of maturity-onset diabetes-of-youth (MODY)-associated glucokinase mutations on substrate interactions and stability of the enzyme. Biochemical Journal 309(Pt 1): 167–173.
21. Davis EA, Cuesta-Munoz A, Raoul M, Buettger C, Sweet I, et al. (1999) Mutants of glucokinase cause hyperglycaemia- and hyperglycaemia syndromes and may produce fetal manifestation causing persistent hyperinsulinism hyperglycaemia of infancy. Diabet Med 24: 1793–1799.
22. Bakitas M, Lahr G, Van de Bunt M, Marchant C, Lindner M, et al. (2007) Heterogeneity in disease severity in a family with a novel G6PC2 GCK activating mutation causing persistent hyperinsulinism hyperglycaemia of infancy. Diabet Med 24: 1793–1799.
23. Brockelhurst KF, Davies RA, Aguas L (2004) Differences in regulatory properties between human and rat glucokinase regulatory protein. Biochemical Journal 370: 461–467.
24. Erler NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, et al. (2009) The P464L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18: 4083–4092.
25. Chen AL, Shing S, Khanna S, et al. (2009) Identification & Characterization of GCK Mutations

Author Contributions

Conceived and designed the experiments: LV NLB NDT MvdB MH AB
Collected clinical data: JS DG IK. Edited the paper: NLB MvdB DG.
Conceived and designed the experiments: LV NLB NDT IK DG ALG.}

Identification & Characterization of GCK Mutations

PluS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34541
40. Krogf J, Selwood MP, McCarthy MI, Farmer AJ, Owen KR (2011) Prevalence of monogenic diabetes in young adults: a community-based, cross-sectional study in Oxfordshire, UK. Diabetologia 54: 1261–1263.

41. Pruhova S, Dusatkova P, Sumak Z, Kolouskova S, Pedersen O, et al. (2010) Glucokinase diabetes in 103 families from a country-based study in the Czech Republic: geographically restricted distribution of two prevalent GCK mutations. Pediat Diabetes 11: 529–535.

42. Gasperikova D, Tribble ND, Stanik J, Huckova M, Misovicova N, et al. (2009) Identification of a novel beta-cell glucokinase (GCK) promoter mutation (−71G>C) that modulates GCK gene expression through loss of allele-specific Sp1 binding causing mild fasting hyperglycemia in humans. Diabetes 58: 1929–1935.

43. Hager J, Blanche H, Sun F, Vaxillaire NV, Poller W, et al. (1994) Six mutations in the glucokinase gene identified in MODY by using a nonradioactive sensitive screening technique. Diabetes 43: 730–733.

44. Estalella I, Rica I, Perez de Nanclares G, Bilbao JR, Vazquez JA, et al. (2007) Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain. Clin Endocrinol (Oxf) 67: 538–546.

45. Lorini R, Klersy C, d’Ammanzio G, Masso O, Minuto N, et al. (2009) Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. Diabetes Care 32: 1864–1866.

46. Takeda J, Gidh-Jain M, Xu LZ, Froguel P, Velho G, et al. (1993) Structure/function studies of human beta-cell glucokinase. Enzymatic properties of a sequence polymorphism, mutations associated with diabetes, and other site-directed mutants. J Biol Chem 268: 15200–15204.

47. Stoffel M, Froguel P, Takeda J, Zouali H, Vionnet N, et al. (1992) Human glucokinase gene: isolation, characterization, and identification of two missense mutations linked to early-onset non-insulin-dependent (type 2) diabetes mellitus. Proc Natl Acad Sci U S A 89: 7698–7702.

48. Pinterova D, Ek J, Kolostova K, Pruhova S, Novota P, et al. (2007) Six novel mutations in the GCK gene in MODY patients. Clin Genet 71: 95–96.